Tasigna has worldwide annualized sales of $300M (#msg-49185209) based almost entirely on use in the second-line (Gleevec-refractory) setting. With the newly expanded label, Tasigna’s sales will increase greatly notwithstanding the fact that Tasigna will eventually have to split the first-line CML indication with GSK’s Sprycel and other agents. This can be ascertained from simple arithmetic: Gleevec, the NVS drug that Tasigna bested with ease in a head-to-head study (#msg-50898190), has annual sales of $4B (#msg-49185209).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.